All Oncology News

The FDA approval of brexucabtagene autoleucel established CAR T-cell therapy as a treatment option for patients with relapsed/refractory mantle cell lymphoma.

Tocilizumab may represent a potential treatment option with double action against cytokine storm due to COVID-19 in a subset of patients with active multiple myeloma and severe infection with the virus.

Investigators are exploring a dual HER2-targeting strategy that incorporates tucatinib into a novel combination as second-line therapy for patients with HER2-positive gastric and esophageal cancers.

Jacqueline Claudia Barrientos, MD, MS, discusses treatment considerations for patients with chronic lymphocytic leukemia.

As part of a resubmission plan for a biologics license application for omburtamab in pediatric patients with central nervous system and leptomeningeal metastasis from neuroblastoma, Y-mAbs, the manufacturer of the B7-H3–targeting monoclonal antibody, announced that it is collecting additional granularity data requested by the FDA and anticipates submitting them to the regulatory agency by the end of April 2021.

The FDA has granted a breakthrough therapy designation to bemarituzumab plus modified fluoropyrimidine, leucovorin, and oxaliplatin as a frontline treatment for patients with FGFR2b–overexpressing and HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma.

Regulatory submissions for the combination of apalutamide plus abiraterone acetate and prednisone in the treatment of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer will not be pursued.

William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies.

Health Canada has approved daratumumab injection, a subcutaneous formulation of daratumumab, for use in combination with bortezomib, cyclophosphamide, and dexamethasone in the treatment of patients with newly diagnosed light chain amyloidosis.

A biologics license application has been submitted to the FDA seeking the accelerated approval of balstilimab for use in the treatment of patients with recurrent or metastatic cervical cancer with disease progression on, or following, chemotherapy.

Selinexor resulted in lower rates and slower worsening of pain in patients with advanced unresectable dedifferentiated liposarcoma vs placebo, and may represent a novel option to provide convenience, improved adherence, and reduced caregiver burden vs existing parenteral therapies.

Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ongoing phase 1/2 trial.

The European Commission has approved isatuximab for use in combination with carfilzomib and dexamethasone in the treatment of patients with relapsed multiple myeloma who have received at least 1 previous therapy.

The FDA has granted priority review to 2 supplemental biologics license applications for enfortumab vedotin-ejfv for the treatment of select patients with locally advanced or metastatic urothelial cancer.

As investigators expand their understanding of the biology of endometrial cancer, doors to new treatment approaches are opening, including the use of a variety of combinations that employ targeted therapies and immunotherapies.

Jyoti D. Patel, MD, discusses the evolving use of osimertinib in EGFR-mutant NSCLC and emerging targeted agents for patients with EGFR exon 20 insertion mutations.

The frontline treatment landscape of renal cell carcinoma is exploding with immunotherapy-based options.

Kristen Marrone, MD, discusses the evolving role of postoperative radiotherapy in early-stage non–small cell lung cancer and ongoing trials examining the use of immunotherapy and targeted agents in patients with unresectable stage III disease.

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

Experts from Northern California-based cancer center to join panels responsible for evidence- based recommendations in NCCN Clinical Practice Guidelines and NCCN Guidelines for Patients, among other resources to improve outcomes for people with cancer.

When considering which frontline option to administer to a patient with renal cell carcinoma, it is important to first understand which risk group they belong to.

Yoomi Lee, MD, discusses the safety profile of surufatinib and highlighted future directions for patients with pancreatic and extrapancreatic NETs.

Jacob Sands, MD, discussed current approaches to the treatment of patients with early-stage and locally advanced non–small cell lung cancer.

Sophia George, PhD, and Judith E. Hurley, MD, discuss the importance of the genetic association study, challenges faced with launching such an effort, the key findings from the research, and the clinical implications of the data in the Caribbean as well as the United States

The FDA has approved nivolumab to be combined with select types of chemotherapy for the frontline treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Tazemetostat as a single agent or in combination with zanubrutinib demonstrated antitumor activity in mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors, suggesting that the agent could be a promising therapeutic option for patients with primary relapsed/refractory disease.

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

Reattaching the greater trochanter to the proximal femur endoprosthesis did not show an improvement in Trendelburg gait or reliance on an assistive ambulatory device vs a soft tissue–only abductor repair in patients with bone cancers.

Lewis Au, MBBS, BMedSci, FRACP, discusses antibody responses to COVID-19 observed in patients with cancer.

The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.